Abstract 2362
Background
Tumour molecular profiling in HNSCC is not routinely incorporated into clinical practice due to lack of validated biomarkers. Liquid biopsy represents noninvasive approach to capture tumour heterogeneity and evolution during treatment. We utilized highly sensitive sequencing method, SafeSEQ, to evaluate plasma circulating tumour DNA (ctDNA) in 2 cohorts of HNSCC patients (pts) with locally advanced (LA) and metastatic disease.
Methods
Cohort 1 included 54 pts with LA HNSCC treated with cisplatin chemoradiotherapy. Plasma was obtained at baseline, end of treatment (EOT) and disease progression (PD) and compared to baseline tissue mutation status. Cohort 2 included 15 pts with metastatic disease who received nivolumab, plasma results were compared at baseline and post 2ndcycle. Sequencing for p53, CDKN2A, HRAS and PIK3CA was performed with SafeSEQ on both plasma and tissue specimens.
Results
51/54 pts with LA disease were evaluated at baseline for tissue (t) and plasma (p) mutation status. P53 was the most common mutation (t: 49%), p: 39%) followed by CDKN2A (t: 17.6%,p: 4%), PIK3CA (t: 9.8%, p: 6%) and HRAS (t: 7.8%, p: 4%). Interestingly 3 (5.8%) pts had detectable HRAS mutations in plasma that were not detected in tissue at baseline. In LA pts whose tumor harbored mutation, ctDNA was detectable in 56% at baseline. Concordance of mutation results between baseline plasma and tissue was 51%. At PD (N = 10) ctDNA exhibited higher rate of detectability compared to baseline and novel mutations emerged in 40% of cases. In cohort 2, 93% (14/15) of metastatic pts exhibited a detectable plasma mutation prior to and during treatment with nivolumab (p53 (100%), CDKN2A (28.6%), HRAS (21%) and PI3KCA (7%)). The pt with no mutation detected was HPV+. During treatment, new plasma HRAS mutations emerged in 3 (21%) pts, while nivolumab did not modulate the overall mutation profile. There was trend for better PFS in pts of cohort 1 whose tumors contained none of analyzed mutations (p = 0.08) while disruptive p53 mutation status based on Poeta classification was not prognostic.
Conclusions
Plasma mutation detection with SafeSEQ is useful in HNSCC for molecular profiling and real-time disease monitoring and may inform clinical trial design.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University funding & Company.
Funding
Sysmex-inostics.
Disclosure
D. Edelstein: Full / Part-time employment: Sysmex-Inostics. K. Stieler: Full / Part-time employment: Sysmex-Inostics. D. Heim: Full / Part-time employment: Sysmex-inostics. F. Holtrup: Full / Part-time employment: Sysmex-inostics. A. Psyrri: Research grant / Funding (institution): Kura; Research grant / Funding (institution): BMS; Advisory / Consultancy: BMS; Honoraria (self): BMS; Honoraria (self): MSD; Advisory / Consultancy: MSD; Honoraria (self): Roche; Advisory / Consultancy: AstraZeneca; Honoraria (self): Leo. All other authors have declared no conflicts of interest.
Resources from the same session
2115 - Preclinical in vivo screening to predict responder patients depend on EGFR status
Presenter: Yejin Kim
Session: Poster Display session 3
Resources:
Abstract
3349 - Interplay between miR-17-5p and MALAT-1 Shapes The Cytokine Storm in Triple Negative Breast Cancer (TNBC) Tumor Microenvironment
Presenter: Raghda Soliman
Session: Poster Display session 3
Resources:
Abstract
4014 - Clinical verification on the relationship between lipid metabolism and the immune microenvironment of breast cancer
Presenter: Wataru Goto
Session: Poster Display session 3
Resources:
Abstract
4158 - The clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer
Presenter: Yunjie He
Session: Poster Display session 3
Resources:
Abstract
5392 - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)
Presenter: Alice Bergamini
Session: Poster Display session 3
Resources:
Abstract
2617 - Oncolytic reovirus as a new anti-tumor strategy in castration resistant prostate cancer
Presenter: Yunlim Kim
Session: Poster Display session 3
Resources:
Abstract
2995 - Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
Presenter: Ali Memarian
Session: Poster Display session 3
Resources:
Abstract
3597 - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Presenter: Christophe Borg
Session: Poster Display session 3
Resources:
Abstract
3430 - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy
Presenter: Juan Marín Jiménez
Session: Poster Display session 3
Resources:
Abstract
1995 - ¬¬Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy
Presenter: Hansol Lee
Session: Poster Display session 3
Resources:
Abstract